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A B S T R A C T
Purpose
In November 2009, the US Preventive Services Task Force (USPSTF) changed its mammography
recommendations from every 1 to 2 years among women age  40 years to personalized
screening decisions for women age 40 to 49 years and screening every 2 years for women age 50
to 74 years.
Methods
We studied mammography trends among 5.5 million women age 40 to 64 years enrolled in a large
national health insurer. We used 2005 to 2009 mammography trends to predict 2012 rates. Our
primary measure was the estimated difference between observed and predicted 2012 annual and
biennial mammography rates. We stratified results by age group and race/ethnicity.
Results
Among women age 40 to 49 years, 2012 mammography rates declined by 9.9% (95% CI,
10.4% to 9.3%) relative to the predicted 2012 rate. Decreases were lowest among black
women (2.3%; 95% CI, 6.3% to 1.8%) and highest among Asian women (17.4; 95% CI,
20.0 to 14.8). Annual mammography rates among women age 50 to 64 years declined by
6.1% (95% CI, 6.5% to 5.7%) by 2012. Regarding biennial mammography rates, women
age 40 to 49 years experienced a 9.0% relative reduction (95% CI, 9.6% to 8.4%). White,
Hispanic, and Asian women age 40 to 49 years demonstrated similar relative reductions of
approximately 9% to 11%, whereas black women had no detectable changes (0.1%; 95% CI,
4.0% to 4.3%). Women age 50 to 64 years had a 6.2% relative reduction (95% CI, 6.6%
to 5.7%) in biennial mammography that was similar among white, Hispanic, and Asian
women. Black women age 50 to 64 years did not have changes in biennial mammography
(0.4%; 95% CI, 2.6% to 3.5%).
Conclusion
Three years after publication of the 2009 USPSTF guidelines, mammography rates declined by 6%
to 17% among white, Hispanic, and Asian women but not among black women. Small reductions
in biennial mammography might be an unintended consequence of the updated guidelines.
J Clin Oncol 33:1067-1074. © 2015 by American Society of Clinical Oncology
INTRODUCTION
Breast cancer is the leading cause of cancer among
women, with an incidence of 121.9 per 100,000 and
a death rate of 22.6 per 100,000 from 2006 to 2010.1
Mortality is substantially higher among black
women than among white, Hispanic, and Asian
women.1 The effect of mammography on breast
cancermortality is controversial. Although early de-
tection and treatment of aggressive breast cancers
reduce the risk of premature mortality,2-10 a recent
Cochrane review concluded that mammograms of-
ten detect nonfatal breast cancer types and that rig-
orous studies did not detect a mortality benefit.11
TheCanadianNational Breast Screening Study sim-
ilarly detectednomortality benefit and estimated an
overdiagnosis rate of 22%.12
Appropriate breast cancer screening intervals
andageof initiationare also controversial.13,14 Some
authorities believe that overuse of mammography
creates unacceptably high rates of anxiety, false-
positive detection, and morbidity as a result of
unneeded procedures.15-18 Others counter that un-
deruse causes preventable deaths.13,14 Before 2010,
the US Preventive Services Task Force (USPSTF)
recommended screening mammography every 1 to
2 years for women age 40 and older.19 Updated
USPSTF guidelines published in November 2009
recommend individual screening decisions for
women age 40 to 49 years that “take patient context
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into account, including the patient’s values regarding specific benefits
and harms” and advocate screening every 2 years forwomen age 50 to
74 years.15 Most other US guidelines continue to recommend mam-
mography either annually or biennially after age 39 years,20-24whereas
guidelines from Europe and Canada are more closely aligned with
USPSTF recommendations.25,26
The release of the USPSTF guidelines generated major contro-
versy and media attention27-30 that might have affected women’s
attitudes about mammography and changed screening patterns. Evi-
dence of the impact of the USPSTF recommendations is scant and
mixed, with smaller studies showing either no changes31,32 ormodest
reductions in screening rates.33,34We examined breast cancer screen-
ing rates before and after the 2009 guideline changes by age and
race/ethnicity group in a large commercially insured population.
METHODS
Data Sources
We studied enrollment information and 2005 to 2012 administrative
claims data (the Optum Clinformatics Data Mart data set; Optum, Eden
Prairie, MN)35 from a large national health plan with members in all 50 US
states.We linkedsociodemographicvariablesderived fromthe2000UScensus
using block group code of residence. We had an ethnicity variable derived
from surname analysis.
Study Population
We included commercially insured women age 40 to 64 years with at
least 11 months of continuous enrollment between 2005 and 2012 and no
evidence of previous mastectomy based on Current Procedural Terminology
and International Classification of Diseases, Ninth Revision procedure codes
(Appendix Table A1, online only).
Outcomes
Wegeneratedquarterly andannual screening rates for all eligiblewomen
and biennial rates for women with at least 23 months of continuous enroll-
ment.We definedwomen as screened for breast cancer if they had at least one
mammography claim during a given interval based on Current Procedural
Terminology, Healthcare Common Procedure Coding System, and Interna-
tional Classification of Diseases, Ninth Revision codes (Appendix Table A1).
Similar to measures used in standardized reporting systems, such as the
Healthcare Effectiveness Data and Information Set,36 thismeasure comprised
codes for both screening and diagnostic mammograms. We included both
types because a woman who receives either is considered screened for breast
cancer for the subsequent 1 to 2 years, because providers ordering such tests
might not appropriately distinguish differences or might be influenced by
reimbursement rates, and because policy changes can be associated with
changes in coding practices. The denominator for each woman was the pro-
portion of the quarter, calendar year, or 2–calendar year period in which she
wasenrolled.Awomanenrolled for21months (outof24) ina2–calendaryear
period would have a denominator of 21/24, or 0.88, rather than 24/24, or 1.0.
Covariates and Stratifying Variables
We classified women as from predominantly white, black, or Hispanic
neighborhoods if they lived in a census block group (geocoding) with at least
75% of members of the respective race/ethnicity. We classified members as
having Asian or Hispanic ethnicity using surname analysis37 and classified
remainingwomenas frommixed-race/ethnicityneighborhoods.Geocoding is
sensitive in detecting black or white race, and surname analysis provides
accurate information on Asian and Hispanic ethnic group.38 This validated
approach of combining surname analysis and census data has positive and
negative predictive values of approximately 80% and 90%, respectively.38We
classifiedwomenduringanygivenperiodasage40 to49yearsor50 to64years.
We removed 0.6%of eligible women because ofmissing geocoded values.We
also classified members by the region of the country in which they resided
(Northeast, South,West, andMidwest).Other covariates included age, neigh-
borhood poverty level (classified as residence in neighborhoods with below
poverty levels of  5%, 5% to 9.9%, 10% to 19.9%, and  20%),39 and
neighborhood education level (classified as residence in neighborhoods with
less thanhigh school education levels of 15%, 15%to24.9%, 25% to39.9%,
and 40%).39
Analysis
We examined sociodemographic characteristics of the populations in
2005, 2009, and 2012.We calculated quarterly, annual, and biennial mam-
mography rates as events per person-time. Because factors such as the
major recession of December 2007 to June 2009 might have affected study
sample characteristics over time, we adjusted time series rates. This in-
volved using weights derived from the 2005 population’s stratum-level
characteristics (education level, poverty level, race/ethnicity, and US re-
gion) applied to subsequent screening rates. We plotted mammography
rates stratified by age group and race/ethnicity, standardized for the vari-
ables that were not used to stratify.
We used interrupted time-series Poisson regression with generalized
estimating equations40,41 to fit a member-level linear model to quarterly,
annual, and biennial screening trends, adjusting for member characteristics
including age, region of residence, poverty level, education level, and race/
ethnicity. For the annual and biennialmodels, we included a 2012 and 2011 to
2012 rate term, respectively, a trend term, and the covariates mentioned
earlier. For themodel estimating annual rates, we excluded the years 2010 and
2011, and we excluded 2009 to 2010 and 2010 to 2011 from biennial models.
The value of interest was the parameter estimate of the 2012 or 2011 to 2012
timepoint term; the exponential of this coefficient subtracted from1estimates
the relative reduction in theobserved2012 rate comparedwith the 2012 rate as
predicted by the baseline trend. We also used the recycled predictions
method42 to estimate predicted and observed 2012 and 2011 to 2012 mam-
mography rates and absolute reductions. To confirm thatmammography rate
changes were coincident with the publication of the USPSTF guidelines, we
performed interrupted time series analysis using the quarterly rates where the
term of interest was the change in the level of screening immediately after the
guidelines were published (ie, beginning in quarter 1 of 2010). To test the
hypothesis thatmammography rates would have reached a plateau after 2009,
weperformedPoissongeneralized estimating equations regression to examine
thedifferencebetween theestimated2009(2008 to2009 forbiennial) and2012
(2011 to2012 forbiennial)mammographyrates, controlling formember-level
covariates. We also conducted a sensitivity analysis using a mammography
measure that excluded diagnostic Current Procedural Terminology and
Healthcare Common Procedure Coding System mammography codes
(76090, 76091, G0204, and G0206), an approach that has a 92% positive
predictive value.43
We conducted analyses using SAS version 9.3 (SAS Institute, Cary,
NC) and STATA 12.1 (StataCorp, College Station, TX). The Institutional
Review Board at Harvard Pilgrim Health Care Institute (Boston, MA)
approved this study.
RESULTS
Table 1 lists the characteristics of the study populations in 2005, 2009,
and 2012. The cohort comprised over 2million women per year who
hadmedian ages of 50 to 51 years over the study period; 43% to 50%
were age 40 to 49 years, and 50% to 57% were age 50 to 64 years.
Approximately 60% lived in high education neighborhoods, and ap-
proximately 47% lived in low poverty neighborhoods; 3% of women
were from predominantly black neighborhoods, 7% to 9% had His-
panic surnames or were from Hispanic neighborhoods, approxi-
mately 3% had Asian surnames, and 15% were from mixed-race/
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ethnicity neighborhoods. Most women were from the South and
Midwest United States.
Annual Screening Rates
Figures 1 and 2 list standardized mammography rates and show
plots of these rates from 2005 to 2012. The estimated observed 2012
rate was 38.8% (95% CI, 38.6% to 39.0%; Table 2), whereas the
predicted 2012 rate was 43.1% (95% CI, 43.1% to 43.2%), a 9.9%
(95% CI,10.4% to9.3%) relative and 4.3% (95% CI,4.6% to
4.1%) absolute reduction. Relative reductions were large among
white, Hispanic, and Asian women (9.4% [95% CI, 10.1% to
8.8%],14.2% [95%CI,15.9% to12.5%], and17.4% [95%
CI,20.0%to14.8%], respectively) in this agegroup.Blackwomen
experienced a nonsignificant relative decrease of 2.3% (95% CI,
6.3% to 1.8%). The estimated observed and predicted 2012 mam-
mography rates among women age 50 to 64 years were 47.5% (95%
CI, 47.3% to 47.7%) and 50.7% (95% CI, 50.6% to 50.8%), respec-
tively, a 6.1% (95%CI,6.5% to5.7%) relative and 3.3% (95%CI,
3.5% to3.0%) absolute reduction. Relative reductionswere again
greatest amongAsianwomen (11.4%; 95%CI,14.0% to8.7%)
and not detectable among black women (0.9%; 95% CI, 1.9%
to 3.8%).
Biennial Screening Rates
Among women age 40 to 49 years, observed and predicted 2011
to 2012 biennial mammography rates were 65.8% (95%CI, 65.4% to
66.1%) and 71.9% (95% CI, 71.8% to 72.1%), respectively, a 9.0%
(95% CI, 9.6% to 8.4%) relative and 6.2% (95% CI, 6.6% to
5.7%) absolute reduction. White, Hispanic, and Asian women age
40 to 49 years experienced similar relative reductions of9.8% (95%
CI, 10.5% to 9.2%), 9.2% (95% CI, 11.0% to 7.2%), and
10.6% (95% CI, 13.6% to 7.5%), respectively, whereas black
women did not experience a relative reduction (0.1%; 95% CI,
4.0% to 4.3%). Observed and predicted biennial mammography
rates amongwomen age 50 to 64 yearswere 76.5% (95%CI, 76.1% to
76.8%) and 81.2% (95% CI, 81.0% to 81.3%), respectively, a 6.2%
(95% CI, 6.6% to 5.7%) relative and 4.7% (95% CI, 5.1% to
4.3%) absolute reduction that was similar among white, Hispanic,
andAsianwomen. Blackwomen age 50 to 64 years did not experience
changes in biennial mammography (0.4%; 95%CI,2.6% to 3.5%).
Quarterly interrupted time series analyses confirmed that screen-
ing rates decreased immediately after the publication of the USPSTF
guidelines amongwomen age 40 to 49 years and 50 to 64 years and in
all race/ethnicity subgroups except black and Asian women age 50 to
64 years (Appendix Table A2, online only). Our sensitivity analyses
examiningdifferences between estimated 2009 and2012 rates showed
a similar pattern of statistically significant reductions across the
subgroups, but their magnitude was reduced (Appendix Table A3,
online only). Using a screening-specific mammography measure,
we found increased relative effect sizes (ie, greater reductions in
screening mammography after the USPSTF guideline changes;
Appendix Table A4, online only) versus our primary analysis that
included any mammogram. Notable findings from our analysis of
rates by region include that women age 50-64 years in theWest and
Midwest experienced relative reductions in biennial screening of
9.0% (95% CI, 10.3% to 7.8%; Appendix Table A5, online
only) and 10.5% (11.4% to9.7%), respectively.
DISCUSSION
Three years after publication of the 2009 USPSTF mammography
guidelines, annual andbiennialmammography rates decreasedby6%
to17%amongwomenwhowerenot fromblackormixed-raceneigh-
borhoods. Reductions were generally larger among women age 40 to
49 years thanwomen age 50 to 64 years, but annual rates declined to a
similar degree compared with biennial rates. Changes also differed by
race/ethnicity; reductions were generally greatest among Asian
women and were not detectable among black women.
Thedifferential reductions by age groupand race/ethnicity could
indicate some level of responsiveness to the USPSTF guidelines. The
majormedia attention27-30 surrounding the guidelinesmight have led
to changes in routine clinical protocols, stimulated discussions be-
tween providers and women, or affected mammography self-referral
patterns. The guidelines recommended against routine screening
among women age 40 to 49 years, and reductions were greater in this










Mean 50.2 51.0 51.3
Standard deviation 6.6 6.8 6.9
Median 50.0 51.0 51.0
Age 40-49, % 49.8 45.0 42.6
Age 50-64, % 50.2 55.0 57.4
Neighborhood poverty
level, %
Low 46.7 45.8 47.2
Low-medium 26.0 25.8 25.7
High-medium 18.6 19.3 18.8
High 8.8 9.1 8.3
Race/ethnicity, %†
White 72.5 69.4 70.0
Black 2.8 3.0 2.8
Asian 2.7 3.2 3.5
Hispanic 7.4 9.0 8.8
Mixed 14.6 15.4 14.9
Neighborhood education
level, %‡
High 60.7 59.5 61.3
High-medium 21.8 21.9 21.5
Low-medium 13.2 13.9 13.2
Low 4.4 4.6 4.1
Region, %
West 13.8 15.2 16.6
South 43.7 49.3 46.7
Midwest 31.6 25.7 27.1
Northeast 10.8 9.7 9.5
Other 0.1 0.0 0.0
Low, low-medium, high-medium, and high denotes living in neighborhoods
with below poverty levels of  5%, 5% to 9.9%, 10% to 19.9%, and 
20%, respectively. Please note that high denotes high poverty (ie, the
poorest neighborhoods).
†See text for explanation of race/ethnicity variable.
‡High, high-medium, low-medium, and low denotes living in neighborhoods
with less than high school education levels of  15%, 15% to 24.9%, 25%
to 39.9%, and  40%, respectively. Please note that high denotes high
education (ie, the neighborhoods with the highest levels of education).
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2005 2006 2007 2008 2009 2010 2011
2102 1102 0102 9002 8002 7002 6002 5002 
Age 40‐49 years 0.40536 0.42839 0.4338 0.43467 0.44349 0.4192 0.42811 0.41956
  White 0.42267 0.4447 0.4502 0.45173 0.4594 0.43507 0.44327 0.43476
  Black 0.32605 0.36058 0.36409 0.35018 0.36808 0.35276 0.36837 0.37828
  Hispanic 0.37536 0.40433 0.40837 0.41407 0.42517 0.38934 0.40509 0.39098
  Asian 0.38731 0.40735 0.41424 0.41895 0.42551 0.39968 0.40149 0.3783
  Mixed 0.36573 0.38806 0.39397 0.39045 0.40185 0.38396 0.39218 0.38731
 
Age 50‐64 years 0.48957 0.50539 0.51239 0.50984 0.5191 0.50838 0.51295 0.50004
  White 0.50832 0.52174 0.52853 0.52669 0.53409 0.52377 0.5271 0.51406
  Black 0.41726 0.44229 0.46193 0.44215 0.45175 0.458 0.46545 0.47268
  Hispanic 0.44797 0.47079 0.4675 0.47014 0.48443 0.46337 0.47614 0.4607
  Asian 0.45131 0.47768 0.48521 0.48772 0.50631 0.49697 0.49795 0.47953
  Mixed 0.44541 0.46227 0.47448 0.46778 0.48003 0.47148 0.47726 0.46445
2012
Age 40‐49 years
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Age 40‐49 years



















2005 2006 2007 2008 2009 2010 2011 2012
Age 40‐49 years
Age 50‐64 years
Fig 1. Adjusted annual mammography rates before and after the November 2009 US Preventive Services Task Force breast cancer screening guideline changes:
(A) overall; (B) predominantly white neighborhood; (C) predominantly black neighborhood; (D) Hispanic ethnicity; (E) Asian ethnicity; and (F) mixed-race neighborhood.
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 2005-2006 2006-2007 2007-2008 2008-2009 2009-2010 2010-2011 2011-2012
Age 40‐49 years 0.66105 0.68092 0.67533 0.6784 0.66559 0.65494 0.64344
  White 0.68184 0.70144 0.69603 0.6996 0.68467 0.67425 0.65941
  Black 0.55972 0.58782 0.56697 0.56613 0.56564 0.56319 0.57483
  Hispanic 0.63024 0.64938 0.65214 0.6564 0.64743 0.62805 0.6245
  Asian 0.63143 0.65462 0.65049 0.65578 0.64457 0.63057 0.61282
  Mixed 0.61083 0.63012 0.6208 0.62095 0.61279 0.60599 0.60201
 
Age 50‐64 years 0.74263 0.76102 0.74757 0.74796 0.74861 0.741 0.72332
  White 0.76269 0.77985 0.76668 0.7663 0.76368 0.75805 0.73663
  Black 0.66095 0.69641 0.67158 0.66007 0.67315 0.66632 0.67205
  Hispanic 0.6985 0.708 0.70102 0.70944 0.72498 0.70328 0.69463
  Asian 0.70391 0.72741 0.71571 0.7275 0.73717 0.73004 0.71009






















































































































































































Fig 2. Adjusted biennial mammography rates before and after the November 2009 US Preventive Services Task Force breast cancer screening guideline changes:
(A) overall; (B) predominantly white neighborhood; (C) predominantly black neighborhood; (D) Hispanic ethnicity; (E) Asian ethnicity; and (F) mixed-race neighborhood.
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group. Inaddition, theUSPSTFrecommended thatwomen in this age
group make personalized decisions with their health care providers;
black women, who have the highest risk of breast cancer mortality,44
showed lesser reductions inmammography comparedwithwomenat
lower risk.
Nevertheless, our study is unable to determine exact reasons for
the patterns we detected, and it is likely that factors such as racial
attitudes about cancer screening,45 trust in consensus guidelines, pre-
viously established screening patterns,46,47 physician financial incen-
tives,48,49 andwillingness to change preventive care patternsmitigated
or reinforced USPSTF recommendations after 2009.
The USPSTF guidelines are highly controversial, and it is infor-
mative to interpret results from the perspective of both USPSTF pro-
ponents and those who favor a more intense screening approach.
Proponents are likely to consider decreases in screening among
womenage40 to49years tobeappropriate, orperhaps even too small,
given studies suggestingpopulation-level harms in this agegroup such
as false-positive tests and unnecessary surgery.15-18 These proponents
might also be reassured that reductions in biennial screening among
women age 50 to 64 years were not large but be concerned that the
reduced rates after 2009might represent an unintended consequence
that could jeopardize Healthy People 2020mammography goals.50
Advocates of amore intense breast cancer screening approach, as
reflected in other consensus guidelines,20-24 are likely to consider all
screening reductionsconcerning.Theseadvocatesmight consider that
decades of progress in increasing screeningmay have been reversed.
Our findings demonstrating small to moderate decreases in
mammography after 2009 are consistent with two smaller shorter-
term studies that also used administrative data. Sharpe et al34
studied older women usingMedicare part B data and found a 4.3%
decline in 2010 mammography versus 2009 mammography rates.
A study using a Vermont mammography registry also found a
larger reduction among women age 40 to 49 years (4.8%) than
women age 50 to 74 years (3.0%).33 A third study using health
insurance claims data found slight trend increases in monthly
mammography after the USPSTF guideline changes51 but used a
more restrictive definition of breast cancer screening that used only
tests coded as screening mammograms. As mentioned earlier, we
intentionally included both screening and diagnostic mammo-
grams to provide a broad measure of population screening rates
given that women are considered screened for breast cancer if they
receive either a screening or diagnostic mammogram. Two studies
using self-reported data found no change in mammography after
2009. Pace et al32 found that mammography rates between 2008








and Observed 2012 Rate (%)
Estimated‡ Relative Difference
Between Predicted and
Observed 2012 Rate (%)
Rate 95% CI Rate 95% CI Difference 95% CI Difference 95% CI
Annual
Age 40-49 years 38.8 38.6 to 39.0 43.1 43.1 to 43.2 4.3 4.6 to 4.1 9.9 10.4 to 9.3
White 40.4 40.2 to 40.7 44.8 44.7 to 44.8 4.3 4.6 to 4.0 9.4 10.1 to 8.8
Black 34.2 33.0 to 35.4 35.2 34.8 to 35.6 1.0 2.3 to 0.4 2.3 6.3 to 1.8
Hispanic 35.4 34.8 to 36.0 41.3 41.0 to 41.5 5.9 6.6 to 5.2 14.2 15.9 to 12.5
Asian 34.7 33.8 to 35.6 41.9 41.5 to 42.3 7.2 8.3 to 6.1 17.4 20.0 to 14.8
Mixed 35.6 35.1 to 36.1 38.8 38.6 to 39.0 3.2 3.8 to 2.7 8.1 9.6 to 6.6
Age 50-64 years 47.5 47.3 to 47.7 50.7 50.6 to 50.8 3.3 3.5 to 3.0 6.1 6.5 to 5.7
White 49.0 48.8 to 49.2 52.3 52.2 to 52.4 3.3 3.6 to 3.1 6.0 6.5 to 5.6
Black 43.9 42.8 to 44.9 44.0 43.6 to 44.5 0.2 1.4 to 1.0 0.9 1.9 to 3.8
Hispanic 43.2 42.6 to 43.9 47.0 46.7 to 47.3 3.8 4.6 to 3.0 7.6 9.2 to 5.8
Asian 43.4 42.4 to 44.5 49.0 48.5 to 49.5 5.6 6.9 to 4.3 11.4 14.0 to 8.7
Mixed 43.3 42.8 to 43.7 46.3 46.2 to 46.5 3.1 3.6 to 2.5 6.2 7.4 to 5.1
Biennial
Age 40-49 years 65.8 65.4 to 66.1 71.9 71.8 to 72.1 6.2 6.6 to 5.7 9.0 9.6 to 8.4
White 67.4 67.0 to 67.9 74.4 74.2 to 74.6 7.0 7.5 to 6.4 9.8 10.5 to 9.2
Black 58.9 56.8 to 61.1 59.0 58.2 to 59.7 0.0 2.5 to 2.5 0.1 4.0 to 4.3
Hispanic 62.8 61.6 to 63.9 68.8 68.3 to 69.2 6.0 7.4 to 4.6 9.2 11.0 to 7.2
Asian 62.3 60.5 to 64.1 69.4 68.6 to 70.1 7.1 9.3 to 4.9 10.6 13.6 to 7.5
Mixed 61.7 60.7 to 62.6 65.6 65.2 to 65.9 3.9 5.0 to 2.8 6.2 7.8 to 4.5
Age 50-64 years 76.5 76.1 to 76.8 81.2 81.0 to 81.3 4.7 5.1 to 4.3 6.2 6.6 to 5.7
White 78.0 77.6 to 78.4 83.4 83.3 to 83.6 5.4 5.9 to 5.0 7.0 7.5 to 6.4
Black 71.0 69.2 to 72.8 71.3 70.6 to 72.1 0.4 2.5 to 1.8 0.4 2.6 to 3.5
Hispanic 72.1 70.9 to 73.2 76.0 75.5 to 76.5 3.9 5.4 to 2.5 5.7 7.6 to 3.8
Asian 72.8 70.9 to 74.8 78.3 77.4 to 79.1 5.5 7.9 to 3.0 7.4 10.4 to 4.4
Mixed 72.7 71.8 to 73.5 75.1 74.7 to 75.4 2.4 3.4 to 1.4 3.3 4.6 to 1.9
Estimated using the recycled predictions method from Poisson generalized estimating equations regression, controlling for covariates listed in the text.
†Predicted based on 2005 to 2009 screening trends and estimated using the recycled predictions method from Poisson generalized estimating equations
regression, controlling for covariates listed in the text.
‡Estimated from Poisson generalized estimating equations regression, controlling for covariates listed in the text, by exponentiating the parameter estimate of the
2012 term, subtracting from 1, and multiplying by 100.
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and 2011 were unchanged in the 40- to 49-year and 50- to 74-year
age groups. Similarly, Howard and Adams31 detected no change
between 2010 and earlier years. It is possible that the substantial
media attention to and criticisms of the USPSTF guideline
changes27-30 might have differentially changed response or recall
bias over time. Investigators have previously found that self-
reported data overestimate cancer screening.52
We believe that our study, comprising more than 2 million
women per year, provides results generalizable to commercially in-
sured women. The insurer whose data we studied contractually re-
quires that all claims be submitted, sowe likely have a precise estimate
of screening rates. Our large sample size allowed us to generate addi-
tional insights by stratifying both by age group and race/ethnicity,
demonstrating, for example, potential differential responsiveness to
the guidelines.
Our study has four main limitations. We assumed that the in-
creases in screening from 2005 to 2009 were linear and would have
continued at the same rate until 2012 in the absence of the USPSTF
guidelines. We cannot rule out the possibility of a nonlinear trend or
other factors that could have influenced screening patterns after 2009.
However, our finding of a decrease in rates immediately after publica-
tion of the USPSTF guidelines and concomitant major media cover-
age provides strong evidence of a causal link.53 Furthermore, only
examining rates before and after the guidelines change amounts to an
uncontrolled pre-post design, which is invalid for causal infer-
ence.53,54 The Cochran group54 and Shadish et al53 recognize inter-
rupted time series design, the approach we used, as the strongest
quasi-experimental design that controls for most common threats to
validity (except co-interventions). In addition, the assumption of a
nonlinear flattening of trend after 2009 is also an assumption and one
that might have less support given historically increasing trends in
breast cancer screening. Furthermore, even presuming a flattened
trendafter 2009,wedetected statistically significant reductions among
all nonblack women, although such decreases were attenuated. The
latter approach provides perhaps a lower bound on the impact of the
2009USPSTF guidelines change. However, using a screening-specific
mammography measure, we detected larger reductions after the
USPSTF guideline changes (Appendix Table A4), whichmight repre-
sent an upper boundof impacts. Given that the overwhelmingmajor-
ity of diagnostic and screening mammograms ultimately do not lead
to a breast cancer diagnosis, women undergoing either test type are
effectively screened for the subsequent 1 or 2 years. As a result and
because providers might not code screening mammograms correctly
(especially after a policy change that might reduce revenue),43 we
believe thatourprimarymammographymeasure,which includedany
mammogram and is consistent with the well-established Healthcare
Effectiveness Data and Information Set measure,36 is most appropri-
ate, while also leading to amore conservative estimate of the USPSTF
guidelines effect compared with a screening-specific measure. Al-
though our results should be generalizable to the commercially
insured population under age 65 years given the large size of the
insurer whose data we examined, this data set is associated with
several limitations. We were unable to assess physician-level inter-
ventions and reimbursement rates unique to the health insurer, but
it is unlikely that these differed substantially from secular patterns
or that providers would be highly aware of the specific health
insurer of their patients or details of how that health insurer reim-
burses differentially from other private health insurers. Our results
may not represent patterns in populations such as the uninsured or
those covered byMedicaid. Finally, our measures of race/ethnicity
were not based on self-report, the gold standard, but rather on
surname analysis and geocoded data. However, this classification
approach has positive and negative predictive values of approxi-
mately 80% and 90%, respectively.38
In conclusion, we found that mammography decreased among
nonblack women after 2009 and in a manner mostly consistent with
updated USPSTF mammography guidelines. For proponents of the
guidelines, ourfindings imply somedegreeof success inpromulgation
of the recommendations but a need to promote biennialmammogra-
phy to avoid downward trends.
Thosewho favor amore intense screeningapproach shouldwork
to promote screening in all age and demographic groups, perhaps
focusing more on younger Hispanic and Asian women who experi-
enced the largest decreases. A key future research priority will be to
examine potential benefits (such as fewer false-positive tests and un-
necessary surgeries) and unintended consequences (such as reduced
biennial screening rates and increased breast cancer death) of the
guideline changes.
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Appendix
Regression Model for Our Annual and Biennial Analyses
● Regression type: generalized estimating equations regression, person-level with one record per person-time interval
● Distribution: Poisson
● Clustering variable: subject ID
● Type: first-order autoregressive
● Regression model: Mammography rate  0  1*calendar_year_period  2*2012/2011-12_period  3*age 
4*region_dummies 5*education_level_dummies 6*poverty_level_dummies 7*race_category_dummies
Example of Numerator and Denominator Construction
For our annual outcome, a woman who was continuously enrolled from January 1, 2005, until December 31, 2012, would initially
contribute eight records for each of the calendar years of 2005, 2006, 2007, 2008, 2009, 2010, 2011, and 2012, although 2010 and 2011 are
ultimately excludedbecauseweestimate thedifferencebetween2012expectedandactual rates.This samewomanwould contribute seven
records for the biennial outcome (2005 to 2006, 2006 to 2007, 2007 to 2008, 2008 to 2009, 2009 to 2010, 2010 to 2011, and 2011 to 2012,
although 2009 to 2010 and 2010 to 2011 are ultimately excluded. For the biennial outcome, if a woman was screened twice (or more) in
the given 2-year period, that would still only count as a 1 in the numerator. The same holds for the annual outcome, where the outcome
for a given woman was binary nomatter howmanymammographies occurred in the 1-year period of interest.
Table A1. Claims-Based Codes Used to Define Numerator Events and Exclude Women From the Denominator
Code Type CPT Codes HCPCS Codes
ICD-9 Diagnosis
Codes ICD-9 Procedure Codes















19180, 19200, 19220, 19240,
19303, 19304, 19305,
19306, 19307
L8600, L8000, L8010, L8020,
L8030, L8001, L8002,
L8015, L8035, L8039
8541, 8542, 8543, 8544,
8545, 8546, 8547,
8548
Abbreviations: CPT, Current Procedural Terminology; HCPCS, Healthcare Common Procedure Coding System; ICD-9, International Classification of Diseases,
Ninth Revision.
Table A2. Relative Level and Trend Changes in Quarterly Mammography Rates From Before to After the 2009 US Preventive Services Task Force
Mammography Guidelines Change
Age and Race
Relative Level Change (%) Relative Trend Change† (%)
Rate 95% CI Rate 95% CI
Age 40-49 years 6.46 6.83 to 6.09 0.24 0.19 to 0.29
White 6.24 6.67 to 5.80 0.23 0.17 to 0.29
Black 6.58 9.04 to 4.06 1.13 0.78 to 1.48
Hispanic 9.53 10.71 to 8.33 0.20 0.03 to 0.37
Asian 6.00 7.86 to 4.10 0.53 0.79 to 0.27
Mixed 5.56 6.57 to 4.53 0.35 0.21 to 0.49
Age 50-64 years 2.07 2.35 to 1.79 0.01 0.05 to 0.03
White 2.01 2.34 to 1.69 0.04 0.09 to 0.00
Black 0.74 2.48 to 1.03 0.71 0.48 to 0.95
Hispanic 3.62 4.75 to 2.49 0.10 0.05 to 0.25
Asian 1.65 3.44 to 0.17 0.45 0.68 to 0.21
Mixed 1.87 2.64 to 1.10 0.02 0.08 to 0.12
Estimated from Poisson generalized estimating equations regression, controlling for covariates listed in the text, by exponentiating the parameter estimate of the
level change term, subtracting from 1, and multiplying by 100.
†Estimated from Poisson generalized estimating equations regression, controlling for covariates listed in the text, by exponentiating the parameter estimate of the
trend change term, subtracting from 1, and multiplying by 100.
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Difference Between 2009 and
2012 Rate (%)
Estimated† Relative Difference
Between 2009 and 2012
Rate (%)
Rate 95% CI Rate 95% CI Difference 95% CI Difference 95% CI
Annual
Age 40-49 years 42.9 42.8 to 43.0 40.1 40.0 to 40.3 2.8 2.9 to 2.7 4.5 4.9 to 4.2
White 44.5 44.4 to 44.6 41.7 41.5 to 41.9 2.8 2.9 to 2.7 4.5 4.9 to 4.1
Black 34.9 34.5 to 35.3 35.7 34.7 to 36.7 0.8 0.2 to 1.4 5.0 2.2 to 7.8
Hispanic 40.9 40.6 to 41.1 37.1 36.6 to 37.6 3.7 4.0 to 3.5 6.7 7.9 to 5.5
Asian 41.5 41.1 to 41.8 36.1 35.4 to 36.8 5.3 5.6 to 5.0 11.0 12.7 to 9.2
Mixed 38.6 38.4 to 38.7 36.8 36.4 to 37.2 1.7 1.9 to 1.5 2.4 3.4 to 1.3
Age 50-64 years 50.5 50.5 to 50.6 48.4 48.2 to 48.5 2.1 2.2 to 2.1 2.9 3.2 to 2.6
White 52.2 52.1 to 52.2 49.8 49.7 to 50.0 2.3 2.4 to 2.2 3.2 3.5 to 2.9
Black 43.8 43.4 to 44.2 45.0 44.2 to 45.8 1.2 0.8 to 1.6 5.0 3.2 to 6.9
Hispanic 46.7 46.4 to 47.0 44.6 44.1 to 45.1 2.1 2.4 to 1.9 2.8 3.9 to 1.6
Asian 48.5 48.0 to 48.9 45.3 44.5 to 46.1 3.2 3.5 to 2.8 4.2 6.0 to 2.4
Mixed 46.1 45.9 to 46.3 44.3 43.9 to 44.6 1.9 2.0 to 1.7 2.3 3.1 to 1.5
Biennial
Age 40-49 years 71.8 71.7 to 71.9 66.5 66.3 to 66.8 5.3 5.4 to 5.1 7.2 7.5 to 6.8
White 74.3 74.1 to 74.4 68.2 67.9 to 68.6 6.0 6.2 to 5.8 8.0 8.4 to 7.5
Black 58.9 58.2 to 59.7 59.0 57.5 to 60.5 0.1 0.7 to 0.9 0.2 2.2 to 2.6
Hispanic 68.4 68.0 to 68.8 64.2 63.4 to 65.0 4.2 4.7 to 3.8 5.5 6.7 to 4.3
Asian 69.1 68.4 to 69.7 63.5 62.2 to 64.7 5.6 6.2 to 5.0 7.7 9.5 to 5.9
Mixed 65.5 65.2 to 65.8 62.1 61.5 to 62.8 3.4 3.7 to 3.0 5.2 6.1 to 4.2
Age 50-64 years 81.1 81.0 to 81.2 76.6 76.4 to 76.9 4.5 4.6 to 4.4 5.9 6.2 to 5.6
White 83.4 83.2 to 83.5 78.2 77.9 to 78.4 5.2 5.3 to 5.1 6.7 7.0 to 6.4
Black 71.5 70.8 to 72.1 70.5 69.2 to 71.7 1.0 1.6 to 0.4 1.8 3.5 to 0.1
Hispanic 75.7 75.2 to 76.1 73.2 72.3 to 74.0 2.5 2.9 to 2.1 3.3 4.4 to 2.1
Asian 77.9 77.1 to 78.6 74.3 72.9 to 75.6 3.6 4.2 to 3.0 4.3 6.1 to 2.6
Mixed 75.1 74.8 to 75.4 72.4 71.8 to 73.0 2.7 3.0 to 2.4 4.0 4.8 to 3.3
Estimated using the recycled predictions method from Poisson generalized estimating equations regression, controlling for covariates listed in the text.
†Estimated from Poisson generalized estimating equations regression, controlling for covariates listed in the text, by exponentiating the parameter estimate of the
pre-post term, subtracting from 1, and multiplying by 100.
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Table A4. Estimated Relative Change in Annual and Biennial Mammography Rates Before and After the 2009 US Preventive Services Task Force Guideline
Changes, Using a Screening-Specific Mammography Measure
Age and Race
Relative Change, Presuming Flattening of
Trend After 2009 (%)
Relative Change, Presuming a Continuation of
2005-2009 Trends After 2009 (%)
Rate 95% CI Rate 95% CI
Annual
Age 40-49 years 8.7 9.0 to 8.3 19.1 19.6 to 18.6
White 8.6 9.1 to 8.2 18.4 19.0 to 17.8
Black 0.6 2.2 to 3.5 12.9 16.6 to 9.1
Hispanic 11.2 12.4 to 10.0 25.1 26.7 to 23.5
Asian 14.2 16.0 to 12.4 24.7 27.2 to 22.2
Mixed 6.7 7.8 to 5.6 18.0 19.4 to 16.6
Age 50-64 years 6.7 7.8 to 5.6 18.0 19.4 to 16.6
White 6.4 6.7 to 6.0 14.1 14.6 to 13.6
Black 1.1 0.8 to 3.0 8.5 11.2 to 5.8
Hispanic 6.7 7.9 to 5.5 18.5 20.0 to 16.8
Asian 7.5 9.3 to 5.7 19.3 21.8 to 16.7
Mixed 5.5 6.3 to 4.7 14.3 15.5 to 13.2
Biennial
Age 40-49 years 10.0 10.4 to 9.7 17.3 17.9 to 16.8
White 10.8 11.2 to 10.4 17.8 18.4 to 17.2
Black 3.2 5.6 to 0.8 10.2 14.0 to 6.2
Hispanic 9.2 10.4 to 8.1 20.0 21.7 to 18.2
Asian 9.4 11.2 to 7.5 16.7 19.5 to 13.7
Mixed 7.9 8.9 to 6.9 14.9 16.4 to 13.3
Age 50-64 years 8.6 8.9 to 8.3 14.3 14.8 to 13.9
White 9.3 9.6 to 9.0 14.8 15.4 to 14.3
Black 4.5 6.2 to 2.8 8.3 11.2 to 5.3
Hispanic 6.9 8.0 to 5.8 16.7 18.4 to 14.9
Asian 6.3 8.1 to 4.5 14.5 17.4 to 11.5
Mixed 6.9 7.7 to 6.2 11.7 12.9 to 10.4
NOTE. Measure excluded diagnostic Current Procedural Terminology and Healthcare Common Procedure Coding System mammography codes 76090, 76091,
G0204, and G0206.
Estimated from Poisson generalized estimating equations regression, controlling for covariates listed in the text, by exponentiating the parameter estimate of the
level change term, subtracting from 1, and multiplying by 100.
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and Observed 2012 Rate (%)
Estimated‡ Relative Difference
Between Predicted and
Observed 2012 Rate (%)
Rate 95% CI Rate 95% CI Difference 95% CI Difference 95% CI
Annual
Age 40-49 years
West 35.0 34.5 to 35.5 41.8 41.6 to 42.0 6.8 7.1 to 6.5 15.9 17.3 to 14.6
South 39.0 38.7 to 39.3 42.4 42.3 to 42.5 3.4 3.6 to 3.2 7.8 8.6 to 7.0
Midwest 39.8 39.4 to 40.2 43.6 43.5 to 43.8 3.9 4.1 to 3.6 8.8 9.8 to 7.8
Northeast 41.1 40.5 to 41.7 47.0 46.8 to 47.2 5.9 6.3 to 5.5 10.0 11.3 to 8.7
Age 50-64 years
West 44.6 44.2 to 45.0 49.2 49.0 to 49.4 4.6 4.9 to 4.4 8.9 10.0 to 7.8
South 47.1 46.9 to 47.4 49.9 49.8 to 50.0 2.8 2.9 to 2.6 5.1 5.7 to 4.5
Midwest 49.5 49.1 to 49.8 52.0 51.8 to 52.1 2.5 2.7 to 2.3 4.7 5.5 to 3.9
Northeast 47.8 47.3 to 48.4 53.3 53.0 to 53.5 5.4 5.8 to 5.1 10.0 11.3 to 8.7
Biennial
Age 40-49 years
West 62.3 61.4 to 63.2 69.7 69.4 to 70.1 7.4 8.0 to 6.9 11.2 12.6 to 9.6
South 66.4 65.9 to 67.0 70.8 70.6 to 71.0 4.3 4.7 to 4.0 6.3 7.1 to 5.4
Midwest 64.1 63.4 to 64.7 73.1 72.8 to 73.3 9.0 9.4 to 8.6 13.0 14.1 to 12.0
Northeast 71.5 70.3 to 72.7 77.2 76.7 to 77.6 5.7 6.4 to 4.9 5.9 7.4 to 4.3
Age 50-64 years
West 72.7 71.9 to 73.5 79.0 78.7 to 79.4 6.4 6.8 to 5.9 9.0 10.3 to 7.8
South 77.6 77.2 to 78.1 79.8 79.6 to 79.9 2.1 2.4 to 1.8 2.6 3.3 to 1.9
Midwest 75.2 74.6 to 75.8 83.6 83.4 to 83.9 8.4 8.7 to 8.0 10.5 11.4 to 9.7
Northeast 79.7 78.6 to 80.8 83.8 83.4 to 84.2 4.1 4.8 to 3.4 5.9 7.4 to 4.3
Estimated using the recycled predictions method from Poisson generalized estimating equations regression, controlling for covariates listed in the text.
†Predicted based on 2005 to 2009 screening trends and estimated using the recycled predictions method from Poisson generalized estimating equations
regression, controlling for covariates listed in the text.
‡Estimated from Poisson generalized estimating equations regression, controlling for covariates listed in the text, by exponentiating the parameter estimate of the
2012 term, subtracting from 1, and multiplying by 100.
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